The COSMIC-313 trial previously assessed the triplet of cabozantinib, nivolumab, and ipilimumab (C+N+I) vs N+I in first-line aRCC. Plasma KIM-1 was assessed at baseline and 4 weeks following the first dose. Both baseline and week 4 KIM-1 levels…
Category: 6. Health
-
Just a moment…
Just a moment… This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Continue Reading
-
Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors
[Transcript]
LBA53 – IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: Primary phase III results (IOB-013/KN-D18)
Hassel: In cutaneous melanoma, we already have quite good immunotherapies. We have the immune…
Continue Reading
-
FSA responds to experts’ criticism over its review of nitrites in processed meat
The Food Standards Agency has defended its rapid review of nitrites in processed meat in response to today’s article from Professors Chris Elliott and Brian Green, saying the findings reflect the latest scientific evidence and were…
Continue Reading
-
From Human Retina to Artificial Eye: KRISS Creates a New Standard for Ophtalmic Imaging
Newswise — The Korea Research Institute of Standards and Science (KRISS, President Lee Ho Seong) has developed a retina-mimicking eye phantom* that faithfully replicates the structural layers and microvascular…
Continue Reading
-
Chula to Host “A Collaborative Meeting on Dengue and Emerging Infectious Diseases (EIDs) 2025”
Newswise — Bangkok, Thailand – November 19, 2025 — The Faculty of Medicine, Chulalongkorn University, in collaboration with the Thai Red Cross Society, Institut Pasteur du Japon, and the School of Global Health,…
Continue Reading
-
Sugar-coated tumours: a new target for pancreatic cancer
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves with a sugar coating. To combat this, they have developed a new antibody therapy that blocks this ‘don’t-attack’ signal, which slows…
Continue Reading
-
Just a moment…
Just a moment… This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Continue Reading
-
Breakthrough study reveals how rabies virus uses few proteins to hijack cells
New antivirals and vaccines could follow the discovery by Australian researchers of strategies used by viruses to control our cells.
Led by Monash University and the University of Melbourne, and published in Nature Communications,…
Continue Reading
